TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02142478

Intervention type: BEHAVIORAL
Intervention: Adapted Exercise for Health (EFH) scheme
Description: 12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week. In February 2012, Centre A introduced some changes to the EFH scheme as follows:~* Pre-scheme meeting with a health trainer to help the patient decide if EFH is for them.~* Participants offered specially tailored group classes (exclusive to EFH participants, e.g. low-impact circuits, Zumba) as well as access to the main gym.~* Opportunities to attend daily.~Although subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members) is also available, this option is not openly advertised on the adapted scheme.

Intervention type: BEHAVIORAL
Intervention: Standard Exercise for Health (EFH) scheme
Description: 12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week.~The scheme includes exclusive EFH gym sessions (i.e. includes EFH participants only) on two to three days of the week, plus subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members).
Study: NCT02912104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human amniotic epithelial cells (hAECs) transplantation
Description: hAECs are prepared and cultured using GMP(Good Manufacturing Practice, GMP) rules, 3×10\^7 hAECs in 4.5ml is separately injected into ovarian tissue by bilateral ovarian artery infusion.
Study: NCT00257309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase + UFH (+ clopidogrel, since 01/97)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary angioplasty
Study: NCT02865083

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traxi Pannus Retractor
Description: traxi® Panniculus Retractor is a retraction device used for retraction of the panniculus during surgical procedures. traxi retracts and holds the panniculus for the duration of the operation, freeing the surgeons hands and those of the staff to better care for the patient.
Study: NCT04626128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS-AX
Description: injectable suspension of small molecule tyrosine kinase inhibitor (TKI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS-AX
Description: injectable suspension of small molecule tyrosine kinase inhibitor (TKI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS-AX
Description: injectable suspension of small molecule tyrosine kinase inhibitor (TKI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS-AX
Description: injectable suspension of small molecule tyrosine kinase inhibitor (TKI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF
Description: Standard of care therapy used to block vascular endothelial growth factor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF
Description: Standard of care therapy used to block vascular endothelial growth factor
Study: NCT00848965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: Corticosteriod, with anti-inflammatory effects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: Corticosteriod, with anti-inflammatory effects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: Corticosteriod, with anti-inflammatory effects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: Corticosteriod, with anti-inflammatory effects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT02582216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D augmented reality
Description: Each treatment period included a 3DARS (3D augmented reality system)training session.All 3DARS training sessions were performed in the same quiet room under the supervision of the same single investigator.The 3DARS training session protocol included two virtual training procedures. The first virtual training procedure consisted of applying a vertical virtual mirror to the display screen, where the non-affected side of the patient's body (such as the right) was symmetrically duplicated by a vertical axis on the affected side (such as the left).The second virtual training procedure consisted of flipping the 3D image horizontally along a vertical axis. This allowed patients to observe the reflection of their non-affected upper extremity as if it was the affected one.
Study: NCT04002466

Intervention type: OTHER
Intervention: Risk factors for anemia
Description: Diet, iron, vitamin B12, folate, inflammation, soil transmitted helminth infection, malaria, other morbidities and other health/nutrition/sociodemographic factors

Intervention type: OTHER
Intervention: Risk factors for anemia
Description: Diet, iron, vitamin B12, folate, inflammation, soil transmitted helminth infection, malaria, other morbidities and other health/nutrition/sociodemographic factors

Intervention type: OTHER
Intervention: Risk factors for anemia
Description: Diet, iron, vitamin B12, folate, inflammation, soil transmitted helminth infection, malaria, other morbidities and other health/nutrition/sociodemographic factors
Study: NCT00593385

Intervention type: DEVICE
Group type: OTHER
Intervention: iCAST covered stent
Description: Iliac stent implantation
Study: NCT04544748

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GNR-051
Description: Anti-PD1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GNR-051
Description: Anti-PD1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GNR-051
Description: Anti-PD1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GNR-051
Description: Anti-PD1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GNR-051
Description: Anti-PD1 monoclonal antibody
Study: NCT02767908

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Participants will receive a tailored support package which will include; Nicotine replacement products, behavioural support, including telephone support, Carbon dioxide measurements, home air quality measurements, signposting to support groups, and self-help materials.For participants who decline a home visit, the above support options will be offered as far as possible through telephone contact and delivered to the extent accepted by the participant. Those who report cessation at 4 weeks and/or three months will be requested to agree to a home visit for CO validation.
Study: NCT01715493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lysozyme 90 mg
Description: Lysozyme 90 mg three times daily for 4 weeks followed by placebo for 4 weeks (plus usual COPD medication)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lysozyme Matching Placebo three times daily for 4 weeks followed by Lysozyme 90 mg three times daily for 4 weeks (plus usual COPD medication)
Study: NCT01892046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-5422
Description: Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety. Maintenance doses at the maximum tolerated dose.
Study: NCT00953589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Ribavirin - oral administration Subjects with body weight \< 65 kg: 800 mg/day Subjects with body weight 65-85 kg: 1000 mg/day Subjects with body weight 86-105 kg: 1200 mg/day Subjects with body weight \> 105 kg: 1400 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Ribavirin - oral administration Subjects with body weight \< 65 kg: 800 mg/day Subjects with body weight 65-85 kg: 1000 mg/day Subjects with body weight 86-105 kg: 1200 mg/day Subjects with body weight \> 105 kg: 1400 mg/day
Study: NCT04626128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF
Description: Standard of care therapy used to block vascular endothelial growth factor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF
Description: Standard of care therapy used to block vascular endothelial growth factor
Study: NCT02722278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Testosterone Undecanoate
Description: Subjects assigned to oral TU treatment will begin at 237 mg TU twice daily. Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg \< 350 ng/dL, decreased if \> 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axiron Testosterone Topical Solution
Description: Subjects assigned to Axiron treatment will begin at 60 mg Axiron every morning. Axiron is applied to the axilla only.~Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg \< 350 ng/dL, decreased if \> 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL.
Study: NCT00402298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Participants will receive an initial dose of 125 mg MDMA orally followed 2.5 hours later by 62.5 mg MDMA orally during the course of a day-long therapy session.
Study: NCT03170544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to glargine
Description: Placebo to glargine, SC, as a single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to MK-1092
Description: Placebo to MK-1092, SC, as a single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to MK-1092
Description: Placebo to MK-1092, SC, as a single dose
Study: NCT00402298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDMA
Description: Participants will receive an initial dose of 25 mg MDMA orally followed 2.5 hours alter by a supplemental dose of 12.5 mg MDMA orally during the course of each of two day-long therapy sessions.
Study: NCT03704363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biosimilar Infliximab
Description: Intravenous infusion(5 mg/kg). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98, unless unacceptable toxicity is encountered.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion. Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98,
Study: NCT01598454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: racotumomab
Description: Dosage form: intradermal injection. Dosage: 0.15 mg; 0.25 mg; 0.4 mg. Frequency: 3 biweekly injections or 6 biweekly injections. Duration: 4 weeks or 10 weeks.
Study: NCT04530721

Intervention type: OTHER
Intervention: no intervention
Description: we don't do any intervention

Intervention type: OTHER
Intervention: no intervention
Description: we don't do any intervention
Study: NCT00953589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: Ribavirin - oral administration Subjects with body weight \< 65 kg: 800 mg/day Subjects with body weight 65-85 kg: 1000 mg/day Subjects with body weight 86-105 kg: 1200 mg/day Subjects with body weight \> 105 kg: 1400 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: Ribavirin - oral administration Subjects with body weight \< 65 kg: 800 mg/day Subjects with body weight 65-85 kg: 1000 mg/day Subjects with body weight 86-105 kg: 1200 mg/day Subjects with body weight \> 105 kg: 1400 mg/day
Study: NCT01890837

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
Study: NCT04140630

Intervention type: OTHER
Intervention: No intervention
Description: No intervention; 1 week observational study

Intervention type: OTHER
Intervention: No intervention
Description: No intervention; 1 week observational study
Study: NCT02645682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anti-infection CVC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: normal CVC
Study: NCT02139020

Intervention type: OTHER
Intervention: Plasma samples
Description: Plasma samples at baseline (and one whole blood sample) and at every radiological evaluations
Study: NCT04447963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive treatment of facial wrinkles
Description: Application of radiofrequency field which provides controlled heating to the skin.Therapeutic effect is observed when the tissue temperature reaches 40-45 degrees Celsius.
Study: NCT03246152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Repeated intravitreal injections of Bevacizumab monthly
Study: NCT04537286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)
Description: Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8 Cisplatin 75 mg/m2，ivgtt，d1 Carilizumab 200mg, ivgtt，d1，q2w
Study: NCT00363376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zonisamide
Description: Zonisamide will be administered at an initial dose of 100 mg/d for 7 days. Subsequently, zonisamide may be increased, based on clinical response and tolerability, by 100mg/d every 7 days to a maximum of 600 mg/d by the end of the sixth week of treatment. The maximum amount of zonisamide allowed during the study will be 600 mg/day. The minimum amount of zonisamide allowed during the study will be 100 mg/d. Zonisamide will initially be given as a single pm dose, but alterations in dosing will be permitted to reduce side effects (e.g., as BID dosing to reduce nausea).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zonisamide
Description: Zonisamide will be administered at an initial dose of 100 mg/d for 7 days. Subsequently, zonisamide may be increased, based on clinical response and tolerability, by 100mg/d every 7 days to a maximum of 600 mg/d by the end of the sixth week of treatment. The maximum amount of zonisamide allowed during the study will be 600 mg/day. The minimum amount of zonisamide allowed during the study will be 100 mg/d. Zonisamide will initially be given as a single pm dose, but alterations in dosing will be permitted to reduce side effects (e.g., as BID dosing to reduce nausea).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: olanzapine will be administered open-label at 5-20 mg/d titrated to optimize response and minimize side effects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: olanzapine will be administered open-label at 5-20 mg/d titrated to optimize response and minimize side effects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: zonisamide ranging from 100mg to 600mg daily
Study: NCT01564563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: Standard treatment of bleeding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: Standard treatment of bleeding

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard therapy
Description: Standard treatment of bleeding

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Two days repeated treatment regimen - low dose administered i.v. (into the vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Two days repeated treatment regimen - high dose administered i.v. (into the vein)
Study: NCT04071769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment
Description: Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments
Study: NCT03265236

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti - modified citrullinate vimentin
Description: patients with early and late RA

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti - modified citrullinate vimentin
Description: patients with early and late RA
Study: NCT03971409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-OX40 Antibody PF-04518600
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study: NCT00363376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugar Pill (placebo)
Description: sugar pill (placebo) for zonisamide
Study: NCT01746082

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/H3N2 variant Vaccine
Description: Investigational influenza virus H3N2v vaccine, a monovalent type A inactivated vaccine (H3N2v MIV) for intramuscular use, is a sterile clear and slightly opalescent suspension prepared from influenza virus propagated in embryonated chicken eggs. The H3N2v MIV contains no preservative. Subjects will be stratified by age (approximately 100 (up to 120) subjects 18-64 years old and approximately 100 (up to 120) subjects \>/=65 years old) to receive two doses of H3N2v MIV, delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/H3N2 variant Vaccine
Description: Investigational influenza virus H3N2v vaccine, a monovalent type A inactivated vaccine (H3N2v MIV) for intramuscular use, is a sterile clear and slightly opalescent suspension prepared from influenza virus propagated in embryonated chicken eggs. The H3N2v MIV contains no preservative. Subjects will be stratified by age (approximately 100 (up to 120) subjects 18-64 years old and approximately 100 (up to 120) subjects \>/=65 years old) to receive two doses of H3N2v MIV, delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart
Study: NCT03099096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within an autoinjector.
Study: NCT04284241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents'Health-Education Handbook
Description: We created a Parents' Health-Education Handbook to teach the newborns' parents to enhance their knowledge of pediatric stone, with a view to changing parents' cognition, attitude and behavior for preventing pediatric stone formation by this cluster randomized control trail.
Study: NCT04864704

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dry needling
Description: Physical therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dry needling
Description: Physical therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dry needling
Description: Physical therapy
Study: NCT03096457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin Sulfate
Description: topical application 2 times a day during 20 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentamidine Isethionate
Description: 3 Intralesional injections at days 1,3 and 5

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical application 2 times a day during 20 days
Study: NCT03816969

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-pressurized air-Q with blocker
Description: It has a drain tube through which a suction tube is passed like the Air-QILA blocker, and Instead of the pilot balloon and inflating cuff, the air-Q SP with blocker incorporates a self-regulating periglottic cuff at the end of this tube , a communication orifice at the junction of the peri-glottic cuff and the airway tube.~This communication between two spaces enables the cuff to dynamically regulate intra-cuff pressure depending on airway pressure. This distinguishing feature of the air-Q SP may result in reduced risk for airway morbidities related to cuff hyperinflation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air-Q ILA blocker
Description: A good seal will provide good ventilation, will guarantee the desired depth of anesthesia at lower gas flows and with lesser leaks to the esophagus, it will not cause rise in intragastric pressure thus preventing regurgitation However, When the cuff pressure is more than the mucosal perfusion pressure, it is likely to either cause postoperative pharyngo-laryngeal symptoms (sore throat, dysphagia, dysphonia) or cause local mucosal trauma and nerve injuries
Study: NCT00584610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-containing IUD (Mirena®)
Description: Levonorgestrel-containing intrauterine device insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Copper-containing IUD (Paraguard®)
Description: Copper-containing intrauterine device insertion
Study: NCT02129257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFLIBERCEPT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Study: NCT03971409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study: NCT01647802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standing attempts with the Vertic'Easy Device
Description: Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standing attempts with the Vertic'Easy Device
Description: Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes.